The short version
Only one company currently supplies this market — there is no backup if it stumbles. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).
Market view
ustekinumab · Injection
1 marketed package NDCs · 1 active manufacturer
Most dispensed: 45 mg/.5mL · Injection, Solution · #1 syringe/carton / .5 ml in 1 syringe · 90 mg/mL · Injection, Solution · #1 syringe/carton / 1 ml in 1 syringe · 130 mg/26mL · Solution · #1 vial, single-use/box / 26 ml in 1 vial, single-use · 45 mg/.5mL · Injection, Solution · #1 vial, single-use/carton / .5 ml in 1 vial, single-use
What changed in the last 90 days
Every detected change for ustekinumab, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Same drug class
Other molecules FDA puts in Interleukin-23 Antagonist, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Ustekinumab in shortage right now?
- No. FDA does not currently list Ustekinumab in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Ustekinumab?
- 5 companies have marketed Ustekinumab in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Ustekinumab cost?
- The typical pharmacy pays about $16,349.56 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.